These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29634620)

  • 1. Population Pharmacokinetics of Intravenous Linezolid in Premature Infants.
    Thibault C; Kassir N; Goyer I; Théorêt Y; Litalien C; Moussa A; Ovetchkine P; Autmizguine J
    Pediatr Infect Dis J; 2019 Jan; 38(1):82-88. PubMed ID: 29634620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants.
    Sicard M; Launay E; Caillon J; Jacqueline C; Legrand A; Deslandes G; Navas D; Rozé JC; Guen CG
    Eur J Clin Pharmacol; 2015 May; 71(5):611-5. PubMed ID: 25740677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C
    Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients.
    Li Y; Fang Q; Wu Z; Huang S; Ge W; Shen J; Zhu H
    Eur J Clin Pharmacol; 2024 Sep; 80(9):1295-1304. PubMed ID: 38801422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration.
    Zheng J; Sun Z; Sun L; Zhang X; Hou G; Han Q; Li X; Liu G; Gao Y; Ye M; Wang H; Yu K
    J Infect Dis; 2020 Mar; 221(Suppl 2):S279-S287. PubMed ID: 32176792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.
    Villa G; Di Maggio P; De Gaudio AR; Novelli A; Antoniotti R; Fiaccadori E; Adembri C
    Crit Care; 2016 Nov; 20(1):374. PubMed ID: 27863531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients.
    Yagi T; Naito T; Doi M; Nagura O; Yamada T; Maekawa M; Sato S; Kawakami J
    Int J Antimicrob Agents; 2013 Oct; 42(4):329-34. PubMed ID: 23988716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients.
    Dong H; Xie J; Wang T; Chen L; Zeng X; Sun J; Wang X; Dong Y
    Int J Antimicrob Agents; 2016 Sep; 48(3):259-64. PubMed ID: 27474469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.
    Merchan LM; Hassan HE; Terrin ML; Waites KB; Kaufman DA; Ambalavanan N; Donohue P; Dulkerian SJ; Schelonka R; Magder LS; Shukla S; Eddington ND; Viscardi RM
    Antimicrob Agents Chemother; 2015 Jan; 59(1):570-8. PubMed ID: 25385115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients.
    Ogami C; Tsuji Y; To H; Yamamoto Y
    J Infect Chemother; 2019 Dec; 25(12):979-986. PubMed ID: 31208925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal and Neurodevelopmental Outcomes Following Linezolid for Coagulase-negative Staphylococcal Infection: Real World Evidence.
    Sicard M; Moussa A; Barrington K; Martin B; Luu TM; Ting JY; Roberts A; Paquette V; Shah PS; Kelly E; Autmizguine J
    Pediatr Infect Dis J; 2020 Jul; 39(7):598-603. PubMed ID: 32091496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.
    Taubert M; Zoller M; Maier B; Frechen S; Scharf C; Holdt LM; Frey L; Vogeser M; Fuhr U; Zander J
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5254-61. PubMed ID: 27324768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.
    Viscardi RM; Othman AA; Hassan HE; Eddington ND; Abebe E; Terrin ML; Kaufman DA; Waites KB
    Antimicrob Agents Chemother; 2013 May; 57(5):2127-33. PubMed ID: 23439637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ontogeny on linezolid disposition in neonates and infants.
    Kearns GL; Jungbluth GL; Abdel-Rahman SM; Hopkins NK; Welshman IR; Grzebyk RP; Bruss JB; Van Den Anker JN;
    Clin Pharmacol Ther; 2003 Nov; 74(5):413-22. PubMed ID: 14586382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.